Related Experiment Video

Updated: May 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and

Xuan Huang1, Cindy H Chau, William D Figg

  • 1Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

Journal of Hematology & Oncology
|July 4, 2012
PubMed

Insights

Despite new treatments, metastatic castration-resistant prostate cancer (mCRPC) remains challenging. This review examines past clinical trials to improve future mCRPC treatment strategies and trial design.

Area of Science:

  • Oncology
  • Clinical Trials
  • Prostate Cancer Research

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) presents a poor prognosis for men, even with docetaxel-based treatments.
  • Recent advancements have introduced new therapies, yet many promising agents have failed in large clinical trials.
  • Optimizing clinical trial design and interpretation is crucial for developing more effective mCRPC strategies.

Purpose of the Study:

  • To review positive and negative clinical trials in mCRPC.
  • To discuss key aspects of clinical trial design for mCRPC.
  • To identify areas for improvement in mCRPC therapeutic development.

Main Methods:

  • Systematic review of published randomized clinical trials in mCRPC.
  • Analysis of clinical trial design elements: target selection, outcome measures, biomarkers, and combination therapies.
  • Evaluation of factors contributing to trial success and failure.

Main Results:

  • Docetaxel-based regimens offer modest survival benefits in mCRPC.
  • Several novel agents approved between 2010-2011, but subsequent trials faced challenges.
  • Clinical trial outcomes highlight the need for refined design and biomarker implementation.

Conclusions:

  • Effective strategies for mCRPC require optimized clinical trial design.
  • Biomarker development and implementation are critical for successful mCRPC drug development.
  • Future research should focus on innovative trial designs and combination therapies for mCRPC.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...